Immunol Feature in Circulation and Thromb in AMI PatientsATAIANCT02704806
Immunologic Analysis of Peripheral Blood and Aspirated Thromb In AMI Patients
An observational study of Immunol Feature in Circulation and Thromb in AMI Patients, run by Jilin University.
Trial summary
Researchers use FCM to analyze the immunol cell feature and its corresponding activation status, as well as the thromb aspirated through the thromb aspiration device in AMI patients Read more about this study
- Who is it for?
- Ages 30 to 80 years
- Conditions the study is for
- Immunol Feature in Circulation and Thromb in AMI Patients
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- Apr 2016to Apr 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Acute myocardial infarction patients
Who may be able to join
- uncomplicated AMI patients
Who cannot join
- any self immune disease and recent (within 1 month) or any chronic infection
About this study
Official title: Immunologic Analysis of Aspired Thromb and Circulatory Immune Cell in AMI Patients
Researchers use FCM to analyze the immunol cell feature and its corresponding activation status, as well as the thromb aspirated through the thromb aspiration device in AMI patients
What is being measured
The primary outcome is the main question the study is designed to answer.
immunologic feature of AMI patients
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Mar 2016 (estimated)
- Study startApr 2016
- Primary completionApr 2017 (estimated)
- Study completionApr 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Immunol Feature in Circulation and Thromb in AMI PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jilin University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mingyou Zhang, Jilin University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02704806
- Sponsor's protocol ID
- Cthromb20160401
- Acronym
- ATAIA
- Status last verified
- Mar 2016
- First submitted
- 5 Mar 2016
- Last updated
- 10 Mar 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Immunologic Analysis of Aspired Thromb and Circulatory Immune Cell in AMI Patients
- ClinicalTrials.gov ID
- NCT02704806
- Acronym / sponsor ID
- ATAIA / Cthromb20160401
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Jilin UniversityUniversity, hospital or other
- Study start
- Apr 2016
- Primary completion
- Apr 2017 (estimated)
- Study completion
- Apr 2018 (estimated)
- First posted
- 10 Mar 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Researchers use FCM to analyze the immunol cell feature and its corresponding activation status, as well as the thromb aspirated through the thromb aspiration device in AMI patients
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 30 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Acute myocardial infarction patients
Key inclusion criteria (1 listed)
- uncomplicated AMI patients
Key exclusion criteria (1 listed)
- any self immune disease and recent (within 1 month) or any chronic infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
immunologic feature of AMI patients
Time frame: 1 month
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2016.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Immunol Feature in Circulation and Thromb in AMI Patients, run by Jilin University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Mar 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
immunologic feature of AMI patients (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2016.